Colorectal Cancer Clinical Trial
Official title:
Clinical Study of Gastric Cancer, Colorectal Cancer and Bladder Cancer Based on Liquid Biopsy
Gastric cancer and colorectal cancer are common gastrointestinal malignancies in the
world.Early cancer generally has no obvious symptoms. Endoscopy is the "gold standard"for the
diagnosis of gastric cancer and colorectal cancer.gastric cancer and colorectal cancer
treatment mainly includes surgery and medication.Compared with traditional diagnosis and
treatment methods, the application of gene detection technology, especially high-throughput
sequencing technology (NGS) in tumor diagnosis and treatment, performs multi-dimensional and
multi-target detection of cancer-related genes, which can quickly and accurately determine
the target gene mutations Morphology and expression differences, so as to provide
personalized guidance to patients in terms of medication, treatment or prognosis evaluation,
which can save a lot of time and treatment costs, and improve the overall treatment effect
and patient quality of life.
Cystoscopy and biopsy sampling pathological testing are the gold standard for bladder cancer
diagnosis, and have been widely used in clinical diagnosis and prognosis judgment. However,
cystoscopy is cumbersome, expensive, and often causes pain to the patients under test. At
present, the main clinical non-invasive detection technique for bladder cancer is still the
cytological examination of urinary tract bladder cells in urine, and its sensitivity and
specificity are not good, especially for the diagnosis of early lower grade bladder
cancer.For bladder cancer, tumor tissue (puncture biopsy or surgical resection) DNA, urine
ctDNA, urinary tract exfoliated cell DNA and peripheral blood ctDNA can be used for genetic
testing, but the consistency of the genetic testing results of these four types of samples
has not been verified, especially There is no systematic evaluation of the guidance effect of
non-invasive gene detection of free tumor DNA and urinary tract shed cell DNA in the
diagnosis and treatment of bladder cancer.The corresponding relationship between the
significant mutation genes contained in the DNA derived from bladder urinary tract cancer and
the various types and stages of bladder cancer is not clear.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
| Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
| Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
| Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
| Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
| Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
| Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
| Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
| Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
| Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
| Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
| Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
| Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
| Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
| Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |